Gliomas are the most common primary brain tumors, accounting for a significant portion of brain cancer cases. These tumors arise from the glial cells and can be highly aggressive and challenging to treat. Traditional treatment approaches for gliomas include surgery, radiation therapy, and chemotherapy. However, the effectiveness of these treatments is often limited due to the infiltrative nature of gliomas and their ability to evade the immune system. Immunotherapy has emerged as a promising approach for the treatment of various cancers, including gliomas. Harnessing the power of the immune system to target and eliminate cancer cells, immunotherapy offers a potential breakthrough in glioma management. However, further research is needed to address challenges related to the immunosuppressive tumor microenvironment, identify reliable predictive biomarkers and optimize treatment regimens. With ongoing advancements, immunotherapy is poised to revolutionize the field of glioma treatment and offer new hope to patients with this devastating disease.
Single-cell sequencing techniques allow researchers to study individual cells within a tumor, providing valuable insights into the heterogeneity and molecular characteristics of glioma cells. Spatiotemporal transcriptome analysis goes a step further by integrating the spatial and temporal information of gene expression patterns within the tumor microenvironment. Combining single-cell sequencing with spatiotemporal transcriptome analysis holds great promise for advancing glioma immunotherapy. This integrated approach can lead to the discovery of novel immunotherapeutic targets, the development of personalized treatment strategies, and a deeper understanding of the complex interactions between glioma cells and the immune system. Ultimately, it has the potential to improve patient outcomes and revolutionize the field of glioma treatment.
In this Research Topic, we aim to provide a current overview of the spatiotemporal heterogeneity in the glioma microenvironment and discuss its therapeutic potential. We welcome original research and review articles related to novel immunotherapy strategies for glioma. Perspectives on both clinical and basic studies are welcome for submissions. Potential topics include, but are not limited to:
• Efficacy and resistance mechanisms to immunotherapies in glioma
• Heterogeneity and molecular characteristics of glioma
• Dynamic interactions in glioma
• Immune landscape uncovering in glioma
• Identification of critical biomarkers influencing response to immunotherapy
• Single-cell sequencing and spatiotemporal transcriptome analysis in glioma
Please note: Manuscripts limited to bioinformatic re-analysis of existing datasets without substantial experimental contribution or detailed representation of novel methodologies will not be considered for publication in this section. And in case of using TCGA data for bioinformatic assays, the authors must use updated clinical diagnosis/classification of the samples according to the most recent WHO guidelines (doi: 10.3390/ijms24010157).
Keywords: Glioma, Immunotherapy, Immune Microenvironment, Single-cell Sequencing, Spatiotemporal Transcriptome.
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
